Odyssey Health, Inc.: 10-K filed 2024-11-13

Name: Odyssey Health, Inc.: 10-K filed 2024-11-13
Creator: Odyssey Health, Inc.

What Odyssey Health, Inc. reported in its annual report filed 2024-11-13 (fiscal FY 2024): 31 published measures, 64 facts as tagged in accession 0001683168-24-007967.

This filing

Form: 10-K (annual report)
Filed: 2024-11-13
Fiscal period: fiscal FY 2024
Accession: 0001683168-24-007967 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Odyssey Health, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2024-07-31	586,146	USD
At 2023-07-31	455,793	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2024-07-31	-5,333,749	USD
At 2023-07-31	-6,155,929	USD
At 2022-07-31	-4,643,617	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	-842,316	USD	366
2022-08-01 to 2023-07-31	-5,919,421	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	-1,215,210	USD	366
2022-08-01 to 2023-07-31	-1,474,696	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	180,724	USD	366
2022-08-01 to 2023-07-31	1,449,088	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	1,000,000	USD	366
2022-08-01 to 2023-07-31	-10,061	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2024-07-31	-61,003,146	USD
At 2023-07-31	-60,097,375	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	97,064,040	shares	366
2022-08-01 to 2023-07-31	82,677,354	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	97,064,040	shares	366
2022-08-01 to 2023-07-31	82,677,354	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	-0.01	USD/shares	366
2022-08-01 to 2023-07-31	-0.07	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	-0.01	USD/shares	366
2022-08-01 to 2023-07-31	-0.07	USD/shares	365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	0	USD	366
2022-08-01 to 2023-07-31	0	USD	365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	577,805	USD	366
2022-08-01 to 2023-07-31	2,820,311	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	14,261,075	USD	366
2022-08-01 to 2023-07-31	-5,314,015	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2024-07-31	56,943	USD
At 2023-07-31	405,888	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2024-07-31	5,919,895	USD
At 2023-07-31	6,611,722	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2024-07-31	1,275,996	USD
At 2023-07-31	1,797,656	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2024-07-31	0	USD
At 2023-07-31	49,905	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2024-07-31	96,709,763	shares
At 2023-07-31	79,067,879	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2024-07-31	2,379	USD
At 2023-07-31	36,865	USD
At 2022-07-31	72,534	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2024-07-31	55,572,687	USD
At 2023-07-31	53,862,378	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2024-07-31	31,939	USD
At 2023-07-31	92,457	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2024-07-31	0	USD
At 2023-07-31	0	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	-905,771	USD	366
2022-08-01 to 2023-07-31	-5,919,421	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	1,506,641	USD	366
2022-08-01 to 2023-07-31	2,122,375	USD	365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	1,538	USD	366
2022-08-01 to 2023-07-31	3,416	USD	365

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	518,476	USD	366
2022-08-01 to 2023-07-31	614,083	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	9,265	USD	366
2022-08-01 to 2023-07-31	8,677	USD	365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	97,900	USD	366
2022-08-01 to 2023-07-31	485,300	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	37,376	USD	366
2022-08-01 to 2023-07-31	3,431	USD	365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-08-01 to 2024-07-31	-195,988	USD	366
2022-08-01 to 2023-07-31	248,087	USD	365

Inspect the source

Entity: Odyssey Health, Inc. / CIK 0001626644
Captured: 2026-09-19T11:19:48.570Z
SEC response SHA-256: 1be33e1ca79fd1e1d5399b519a2ef141b4c1191380216b92c135e07a22902f7b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001626644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))